首页> 外国专利> ASSESSING RESPONSIVENESS OF RHEUMATOID ARTHRITIS PATIENTS TO BIOLOGICAL TREATMENT

ASSESSING RESPONSIVENESS OF RHEUMATOID ARTHRITIS PATIENTS TO BIOLOGICAL TREATMENT

机译:评估类风湿性关节炎患者生物治疗的反应性

摘要

The relates to the field of diagnosis and treatment of Rheumatoid Arthritis, in particular of assessing responsiveness of rheumatoid arthritis patients to biological treatment. In particular the it has been found that measurement of MDR1 and/or MRP1 transport activities in the early phase of or before a bDMARD treatment is appropriate to provide a prediction on the effectiveness or success of bDMARD therapy once csDMARD therapy has failed. Thus, the invention relates to an in vitro diagnostic method for assessing the responsiveness of a sDMARD treated RA patient to bDMARD therapy, wherein preferably the patient is in need of a switch or modification of the sDMARD therapy by measuring transport activities of the above-mention transporters or their composite activities. The invention also relates to use of kits for the methods of the invention and methods for treatment comprising the diagnosis or prediction of the invention.
机译:涉及类风湿性关节炎的诊断和治疗领域,特别是评估类风湿性关节炎患者生物治疗的反应性。特别地,已经发现,在BDMARD治疗的早期或之前的早期阶段测量MDR1和/或MRP1运输活动适合于提供对BDMARD治疗失败后对BDMARD治疗的有效性或成功的预测。因此,本发明涉及用于评估SDMARD处理RA患者对BDMARD治疗的响应性的体外诊断方法,其中优选地,通过测量上述运输活动,患者需要改变SDMARD疗法运输商或其综合活动。本发明还涉及试剂盒用于本发明的方法和治疗方法,包括本发明的诊断或预测。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号